Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCH 52365 in Newly Diagnosed Glioblastoma Multiforme
NCT00684567Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2005
- Primary completion
- Oct 2007
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of temozolomide in glioblastoma multiforme (GBM), sponsored by Merck & Co.. Started Sep 2005; status: completed.
02
Drugs
temozolomide
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00684567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00684567.